Oncomedicine 2017; 2:61-65. doi:10.7150/oncm.17910

Short Research Paper

Concurrent Capecitabine and Radiation Therapy for High-risk Primary Breast Cancer

Uma Goyal1✉, Tijana Skrepnik1, Rajayogesh Davuluri1, Michele B Ley2, Pavani Chalasani1, Rebecca K Viscusi1, Lauren G Lebeau1, Robert B Livingston1, Justin Famoso1, Victor J Gonzalez1

1. University of Arizona, Tucson, Arizona, United States;
2. Tucson Medical Center, Surgery, Tucson, Arizona, United States


Introduction: Data is limited for concurrent capecitabine-radiotherapy (CCRT) in primary breast cancer. We evaluated outcomes and toxicities of patients at high risk of locoregional recurrence receiving adjuvant CCRT.

Methods: Ten non-metastatic breast cancer patients receiving concurrent treatment were reviewed retrospectively. Capecitabine was given during and after radiation. Toxicity was reviewed using weekly on-treatment visit and follow-up notes.

Results: All patients had stage II-III disease. Four patients had grade 3 skin toxicity during radiation. Capecitabine and RT-related toxicity breaks occurred for 5 and 0 patients, respectively. At 1-month follow-up, 9 patients recovered from acute toxicities sufficiently to start adjuvant capecitabine. At 25 months median follow-up, 1 patient had synchronous local recurrence and distant metastasis (DM), while 3 patients had DM only.

Conclusions: Use of CCRT for breast cancer was associated with significant acute grade 3 dermatitis, however, all patients successfully completed their radiation course without interruption.

Keywords: breast cancer, capecitabine, high-risk, radiation

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Goyal U, Skrepnik T, Davuluri R, Ley MB, Chalasani P, Viscusi RK, Lebeau LG, Livingston RB, Famoso J, Gonzalez VJ. Concurrent Capecitabine and Radiation Therapy for High-risk Primary Breast Cancer. Oncomedicine 2017; 2:61-65. doi:10.7150/oncm.17910. Available from http://www.oncm.org/v02p0061.htm